

Kroger
Prescription
Plans

We provide industry leading care, generating proven outcomes.

Vectra® uses molecular assessment to optimize treatment decisions and drug therapy in patients with rheumatoid arthritis (RA).



Overview

The Vectra test combines multiple serum biomarkers into a single score, ranging from 1 to 100 which is further categorized as low (<30), moderate (30-44), or high (>44), providing clinicians with an objective measure of disease activity. This test is included in the American College of Rheumatology's (ACR) 2019 recommendations for disease activity measures in RA patients.

Vectra assists clinicians in treating-to-target through its ability to predict rapid radiographic progression and assess treatment response. Use of Vectra to make informed decisions and monitor treatment success may help avoid premature therapy changes, while creating significant savings for patients, clinicians, and payers.

Program Highlights

The goal of the program is to increase the number of members safely managed on generics prior to biologic DMARD initiation. This delivers better clinical outcomes while optimizing drug trend and spend for payors.

- Value based contract defined by at least 5% of the tested population with results in the low to moderate category delays a new start on any biologic agent approved by the FDA for the treatment of RA
- Covered benefit for 165,000 members effective January 1, 2019
- 600 members eligible for test, per Rx claims analysis
- Low and moderate Vectra scores targeted for delayed (6 months) biologic DMARD initiation

800.917.4926

www.kpp-rx.com

Enhanced Treatment Results in Savings

\$571k

*Confirmed Annual Drug Savings
Compared to Treatment as Usual*

*6 months of savings is based on \$4,540 per-month net cost for bDMARD; savings after paying for cost of testing.

Vectra® Case Study Outcomes

42 of 56 Members Tested are 6 Months Post-Test

19 Members Not Eligible for Analysis



- ✓ 13 on DMARD Before Test
- ✓ 6 Received High Test Scores

23 Members Receive Low or Mod Score

- ✓ 22 Avoided DMARD (95%)
- ✓ 1 Initiated DMARD (5%)

Score Distribution

Of the 56 members tested, 53% scored low to moderate, and were targeted for delay of therapy.



Clinical Programs Mean Customized Care

95% *Avoided DMARD With
Low/Moderate Scores*

\$30k *Savings Per Compliant
Patient Per Year*

¹Centola M, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE 2013; 8(4): e60635. ²Curtis J, et al. Validation of a novel biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64(12):1794–1803. ³Eastman PS, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012; 415-24.